Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Patients

R&D

Partner Content

R&D
FT Global Pharma & Biotech Summit 2024 banner
Partner Content

FT Global Pharma & Biotech Summit 2024

The Global Pharma and Biotech Summit is the essential annual event for you to stay on top of the latest trends and innovations in life sciences.

R&D
9th CDD For Biologics Summit 2024 banner
Partner Content

9th CDD For Biologics Summit 2024

Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development